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Abstract
Purpose Propranolol, a non-selective b-adrenergic recep-
tor blocker, has been used for the treatment of the patients
with hypertension for more than 50 years. There are several
in vitro and in vivo evidences that b-adrenergic receptor
antagonists inhibit proliferation and angiogenesis and also
increase apoptosis in breast, skin, and colon cancers. The aim
of this study was to investigate the cytotoxic and apoptotic
effects of propranolol and the genes involved in propranolol-
induced apoptosis in multiple myeloma cells.
Methods Time-dependent antiproliferation and apoptotic
effects of propranolol were subsequently determined by
MTT cell proliferation assay, changes in caspase-3 activity,
loss of mitochondrial membrane potential (MMP), and also
the localization of phosphatidylserine in the plasma
membrane. Changes in expression levels of NF-JB path-
way were examined by qRT-PCR array.
Results IC50 values of propranolol on U266 cells were
calculated as 141, 100, and 75 lM after 24-, 48-, and 72-h
propranolol exposure, respectively. There were significant
increases in caspase-3 activity, loss of MMP, and increases
in apoptotic cell population in response to propranolol in
U266 cells in a time- and dose-dependent manner. There
were increases in expression levels of BCL10, TRAF
family members, interleukins, TLR1-4, TNFRSF10B, NF-
jB, and the inhibitors of NF-jB genes, and significant
decreases in expression levels of Bcl-2 in response to
propranolol treatment were observed.
Conclusion These results revealed that propranolol has
antiproliferative and apoptotic effects on multiple myeloma
cells. Being supported with in vivo analyses, propranolol
can be a good and economical way to treat multiple
myeloma patients.
Keywords Multiple myeloma  Propranolol  NF-jB
pathway  Apoptosis
Introduction
Propranolol was successfully developed as a first beta-
blocker in 1960s (Emilien and Maloteaux 1998). Propran-
olol, a non-selective b-adrenergic blocking agent, is used
predominantly for the treatment for hypertension, cardiac
arrhythmias, coronary artery disease, thyrotoxicosis,
migraine headache, and a number of other conditions such
as psychiatric diseases (Emilien and Maloteaux 1998;
Frohlich 1977; Featherstone 1983; Lee et al. 1982). In
recent years, the data obtained from meta-analysis and
in vitro and in vivo experimental studies showed that beta-
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receptor antagonists inhibit tumor proliferation and
metastasis in breast, stomach, skin, and colon cancers
(Masur et al. 2001; Benjamin et al. 2010; Slotkin et al.
2000; Glasner et al. 2010; Benish et al. 2008; Algazi et al.
2004; Park et al. 1995). In vitro, the antiangiogenic bio-
logical activity of propranolol was also shown to inhibit
human brain microvascular endothelial cell tubulogenesis
(Annabi et al. 2009). Propranolol has recently been intro-
duced as a pharmacologic treatment for infantile heman-
giomas (Sidbury 2010; Storch and Hoeger 2010; Le´aute´-
Labre`ze et al. 2008; Sarialioglu et al. 2010; Sans et al.
2009; Sommers Smith and Smith 2002; Love and Sikka
2004; Buckmiller et al. 2010).
Multiple myeloma (MM) is a clonal B-cell malignancy
characterized by the aberrant expansion of plasma cells
within the bone marrow, as well as at extramedullary sites
(Mahindra et al. 2010). MM accounts for 13.4 % of all
hematologic malignancies diagnosed, 19 % of all deaths
resulting from hematologic malignancies, and 2 % of all
cancer deaths (Mahindra et al. 2010). MM is an incurable
disease, although patient survival has increased with the
availability of novel agents ((Mahindra et al. 2010; Minnema
et al. 2010). Both multiple myeloma and its therapies often
affect the renal, immune, skeletal, hematologic, and nervous
systems (Minnema et al. 2010; Richardson et al. 2007; Elouni
et al. 2010). The resulting organ dysfunctions often impair the
life quality of affected patients, complicate and limit sub-
sequent therapies, and may result in significant mortality.
Our aim in this study was to investigate the in vitro
effects of the non-selective b-adrenergic receptor blocker
propranolol on U266 MM cells and to examine the
mechanisms involved in propranolol-induced apoptosis.
Materials and methods
Cell line and culture conditions
Human U266 multiple myeloma cells were obtained from
German Collection of Microorganisms and Cell Cultures
(Germany). Propranolol was kindly provided by Baskent
University, Department of Hematology (Sanofi Aventis,
Istanbul, Turkey). 10 mM stock solutions of propranolol was
prepared in dimethyl sulphoxide (DMSO) and stored at
-20 C. U266 human multiple myeloma cells were cultured
in RPMI-1640 growth medium containing 10 % fetal bovine
serum and 1 % penicillin–streptomycin at 37 C in 5 % CO2.
Measurement of cell growth by MTT assay
Time-dependent IC50 value (drug concentration inhibits
cell growth by 50 %) of propranolol was determined by
MTT cell proliferation assay. In short, 1 9 104 cells/well
were seeded into 96-well plates containing 100 lL of the
growth medium in the absence or presence of increasing
concentrations of propranolol and then incubated at 37 C
in 5 % CO2 for 24, 48 and 72 h. After incubation period,
cells were treated with 20 lL MTT (5 mg/mL) for 4 h.
Then, plates were centrifuged for 10 min at 1,800 rpm.
After centrifugation, supernatants were removed from the
plates and then the MTT crystals were homogenized by
adding 100 lL DMSO into each well. In order to homog-
enize the pellets more efficiently, the plates were shaken
for 5 min by shaker. Afterward, the plates were read under
570 nm wavelengths by Elisa reader (Thermo Electron
Corporation Multiskan Spectrum, Finland). Finally, IC50
value of propranolol was calculated according to the cell
proliferation plots.
Analysis of caspase-3 enzyme activity
Changes in caspase-3 enzyme activity of the cells, as an
important sign of apoptosis, were examined by caspase-3
colorimetric assay kit (BioVision Research Products,
USA). This assay is based on spectrophotometric detection
of the chromophore p-nitroanilide (pNA) after cleavage
from the labeled substrate DEVD-pNA that can be recog-
nized by caspase-3. In short, the cells (1 9 106 cells/2 mL/
well), induced to undergo apoptosis, were collected by
centrifugation at 1,000 rpm for 10 min. The cells were
lysed by adding 50 lL of chilled 19 Cell Lysis Buffer and
incubated on ice for 10 min before centrifugation at
10,000g for 1 min. Supernatants were transferred to new
Eppendorf tubes, and the reaction mixture was prepared in
96-well plates by adding 50 lL of 29 Reaction Buffer
(containing 10 mM DTT), 50 lL of sample, and 5 lL of
DEVD-pNA substrate and incubated for 2 h at 37 C in
CO2 incubator. At the end of this period, the plate was read
under 405 nm wavelengths by Elisa reader (Thermo
Electron Corporation Multiskan Spectrum, Finland). The
absorbance values are normalized to protein concentrations
determined by Bradford assay as described previously.
Determination of loss in mitochondrial membrane
potential
We have also examined the loss of MMP, another impor-
tant sign of apoptosis, in response to propranolol in U266
cells by JC-1 Mitochondrial Membrane Potential Detection
Kit (Cayman Chemicals, USA). This kit uses JC-1, a
unique cationic dye, to signal the loss of the MMP. JC-1
accumulates in the mitochondria which stain red in non-
apoptotic cells, while in apoptotic cells, the MMP col-
lapses, and thus the JC-1 remains in the cytoplasm as a
monomer that stains green under fluorescent light. Briefly,
the cells (1 9 106 cells/2 mL), induced to undergo
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apoptosis, were collected by centrifugation at 1,000 rpm
for 10 min. Supernatants were removed, pellets were
homogenized by 300 lL of medium, and 30 lL of JC-1
dye was added onto the cells; then, the cells were incubated
at 37 C in 5 % CO2 for 30 min. Then, they were centri-
fuged at 400g for 5 min, supernatants were removed, and
200 lL of assay buffer was added onto the pellets and
vortexed. Then, this step was repeated once more. After-
ward, all pellets were re-suspended with 320 lL assay
buffer and 100 lL from each of them was added into the
96-well plate as triplicates. In healthy cells, the aggregate
red form has absorption/emission maxima of 560/595 nm,
whereas in apoptotic cells, the monomeric green form has
absorption/emission maxima of 485/535 nm. The plate was
read in these wavelengths by fluorescence Elisa reader
(Thermo Varioskan Spectrum, Finland). At the end, green/
red (485/560) values were calculated to determine the
changes in MMP.
Analysis of apoptotic cells by AnnexinV-FITC staining
In addition to the analysis of changes in caspase-3 enzyme
activity and mitochondrial membrane potential as apoptotic
markers, we have also determined the translocation of
phosphatidylserine from the inner membrane to the outer
cell membrane. Initially, 1 9 106 cells were treated with
increasing concentrations of propranolol (50–200 lM) for
24, 48 and 72 h. After the incubation periods, cells were
washed twice with cold PBS and then re-suspended with
1 mL 19 binding buffer. Then, 100 lL of this solution was
added into glass tubes. 5 lL of AnnexinV-FITC and 10 lL
of PI were added onto the solutions. These samples were
vortexed gently and then incubated for 15 min at RT in the
dark. Afterward, 400 lL of 19 binding buffer was added to
each tube, and then they were analyzed by flow cytometry
(BD Facscanto Flowcytometry, Belgium) within 1 h.
Total RNA isolation from cells and reverse
transcriptase-polymerase chain reaction NF-jB
TaqMan array (qRT-PCR TaqMan array)
The cells were incubated in the absence and presence of
increasing concentrations of propranolol for 72 h, and total
RNAs were isolated by using RNA Isolation Kit (High
Pure Isolation Kit, Roche, USA). mRNAs from the total
RNA population were reverse-transcribed into cDNA using
reverse transcriptase enzyme (Transcriptor First Strand
cDNA Synthesis Kit, Roche, USA). The resulting total
cDNA was used in PCR to measure the mRNA levels of
Human NF-jB Pathway (TaqMan Array Human NF-jB
Pathway, Applied Biosystems). This assay panel targets
genes which encode the 5 proteins of the Rel/NFKB fam-
ily: NFKB1, NFKB2, REL A, REL B, and REL. Also, on
the panel, there are genes from families that include the
IkB kinase; IkBs (inhibitor of kB); Toll-like receptor
(TLR); tumor necrosis factor (TNF); tumor necrosis factor
receptors (TNFR); and tumor necrosis factor receptor-
associated factor (TRAF). Additional genes associated with
NF-JB function in apoptosis, immune/inflammation
responses, as well as chemokines and cytokines are inclu-
ded. mRNA levels of HPRT and GSUB were used as
endogenous positive control.
Results
Propranolol inhibited proliferation of U266 human
multiple myeloma cells in a time- and dose-dependent
manner
In order to determine antiproliferative effects of propran-
olol on human U266 MM cells, the cells were incubated
with increasing concentrations of propranolol for 24, 48
and 72 h and MTT cell proliferation assay was conducted.
The results of these assays showed that there were time-
and dose-dependent decreases in cell proliferation as
compared to untreated controls. Different exposure times
resulted in two different IC50 values. IC50 values of pro-
pranolol for 24, 48 and 72 h were calculated from cell
proliferation plots and found to be 100 and 75 lM,
respectively (Fig. 1).
Propranolol increases caspase-3 enzyme activity
in a time- and dose-dependent manner
In order to determine apoptotic effects of propranolol on
U266 MM cells, these cells were incubated with increasing
concentrations of propranolol for 24, 48 and 72 h and
changes in caspase-3 enzyme activities were analyzed.
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Fig. 1 Antiproliferative effects of propranolol on U266 cells. The
IC50 value of propranolol was calculated from cell proliferation plots.
The MTT assays were performed using triplicate samples in at least
two independent experiments. Statistical significance was determined
using two-way analysis of variance, and p \ 0.05 was considered
significant
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There were 1.10-, 1.18-, and 1.50-fold increases in caspase-
3 activity in response to 48-h incubation with 50, 100, and
200 lM propranolol, respectively, as compared to
untreated cells (Fig. 2). The same concentrations of pro-
pranolol increased caspase-3 activity 1.46-, 1.49-, and
1.55-fold after 72-h incubation, respectively (Fig. 2). Pro-
pranolol induced apoptosis in a dose-dependent manner
that is also directly related with the caspase-3 activity.
Propranolol induces the loss of mitochondrial
membrane potential in a time- and dose-dependent
manner
In order to assess the loss of MMP, U266 cells were
exposed to 50, 100, and 200 lM propranolol for 48 and
72 h and JC-1 MMP assay was conducted. The results of
this assay revealed that there were 1.35-, 1.11-, and 82.5-
fold increases in loss of MMP in response to 50, 100, and
200 lM propranolol for 48 h, respectively (Fig. 3). The
same concentrations of propranolol induced loss of MMP
for 1.73-, 2.10-, and 127.69-fold after 72-h incubation as
compared to untreated control group, respectively (Fig. 3).
Propranolol causes the modulation of the cell
membrane resulting in the translocation of PS
from the inner leaflet to the outer one in a time-
and dose-dependent manner
In order to confirm the results of caspase-3 activity and loss
of MMP, FITC AnnexinV/PI double staining was con-
ducted in U266 cells exposed to 50, 100, and 200 lM
propranolol for 24, 48 and 72 h. The results demonstrated
that 48-h incubation of U266 cells with these concentra-
tions of propranolol increased apoptotic cell death by 14,
232, and 555 % as compared to untreated control group
(Figs. 4, 5a), while 72-h incubation increased apoptosis by
48, 370, and 802 %, as compared with untreated controls,
respectively (Figs. 4, 5b).
Changes in expression levels of NF-JB pathway genes
in response to propranolol
In order to analyze the genes involved in NF-jB pathway
regulated by propranolol treatment, U266 cells were treated
with increasing concentrations of propranolol (20, 50, and
100 lM) and expression levels of approximately 80 genes
involved in NF-jB pathway were determined by qRT-PCR
array. According to the array results, the expression levels
of some important genes were changed significantly. For
instance, the expression levels of apoptotic Bcl-10 gene
increased by approximately sevenfold in response to
50 lM propranolol. However, the expression levels of
antiapoptotic Bcl-2 gene decreased around fivefold in
response to the same concentration of propranolol. In
addition, the expression levels of tumor necrosis factor
receptor-associated factor (TRAF) genes increased in
response to increasing concentrations of propranolol. These
genes lead to antiapoptotic events by interacting with
inhibitor of apoptosis proteins (IAPs). There were also
increments and decrements in response to propranolol in
expression levels of TLR family. Importantly, the expres-
sion levels of tumor necrosis factor receptor superfamily
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Fig. 2 Changes in caspase-3 enzyme activity in response to increas-
ing concentrations of propranolol in U266 cells. The results are the
means of two independent experiments. p \ 0.05 was considered
significant
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Fig. 3 Loss of mitochondrial membrane potential in response to
increasing concentrations of propranolol in U266 cells. The results are
the means of two independent experiments. p \ 0.05 was considered
significant
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Fig. 4 FITC AnnexinV/PI double staining of U266 cells treated with
increasing concentrations of propranolol. The results are the means of
two independent experiments. p \ 0.05 was considered significant
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member 10b (TNFRSF10B), an important transducer of
apoptotic signals, increased significantly. There were
4.8-, 156.25-, and 700-fold increases in expression levels
of TNFRSF10B in response to 20, 50, and 100 lM
propranolol, respectively, as compared to control group.
Furthermore, there were 3.86- and 16.6-fold increases in
IL-10 expression levels in response to increasing concen-
trations of propranolol. IL-10 is known to suppress NF-jB
activity, and increase B-cell survival, proliferation, and
antibody production. Treatment of U266 cells with
Fig. 5 Flow cytometric
analysis of apoptosis in U266
cells. Early apoptotic cells
labelled with Annexin-V but not
PI (shown in lower right
quadrant) and apoptotic cells
labelled with Annexin-V and PI
were found in the upper right
quadrant in flow cytometric
graphics
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increasing concentrations of propranolol also caused
increases in the expression levels of IL-6 and IL-8 genes.
Moreover, there were significant changes in the expression
levels of NF-jB in response to propranolol. There were
2.1-, 2.28-, and 6-fold increases in a dose-dependent
manner (10 and 50 lM). Nevertheless, there were also
increases in the expression levels of the inhibitors of NF-
jB. NF-jBIA expression levels decreased approximately
twofold, and NF-jBIB expression increased by fivefold in
response to 20 lM propranolol. In addition, the expression
levels of RIPK1 gene, which is involved in NF-jB pathway
and also cellular necrosis, were shown to be increased for
4.5- and 6.33-fold in 50 and 100 lM propranolol-treated
cells, respectively (Table 1).
Discussion
Propranolol is a non-selective b-adrenergic antagonist and
is widely used clinically for various conditions including
hypertension, anxiety, cardiac arrhythmias, and thyrotoxi-
cosis (Emilien and Maloteaux 1998; Frohlich 1977;
Featherstone 1983; Lee et al. 1982). Clinical benefits have
been observed in combination with COX-2 inhibitors in
postoperative cancer patients, in whom perioperative
treatment resulted in improved immune competence and in
reduced risk of tumor metastasis (Lee et al. 1982; Masur
et al. 2001; Benjamin et al. 2010; Slotkin et al. 2000). It
was therefore inferred that blockade of b-adrenergic
receptor functions would affect tumor development, an
effect that was confirmed by the inhibition of experimen-
tally induced pulmonary adenocarcinoma development
(Park et al. 1995). The contribution of b-adrenergic
receptor functions to tumorigenesis was also reflected by
the suggested antiangiogenic effects of b-blockers on a
tumor-associated endothelial cell model (Park et al. 1995;
Annabi et al. 2009; Sidbury 2010; Sommers Smith and
Smith 2002).
Propranolol may revolutionize the treatment for prob-
lematic hemangiomas that cause imminent functional or
cosmetic sequelae (Storch and Hoeger 2010; Le´aute´-Lab-
re`ze et al. 2008; Sarialioglu et al. 2010; Sans et al. 2009;
Buckmiller et al. 2010). At therapeutic doses, propranolol
is safe and effective in the majority of patients. Early
effects (brightening of the hemangioma surface within
1–3 days after start of therapy) are attributable to vaso-
constriction due to decreased release of nitric oxide.
Intermediate effects are due to the blocking of proangio-
genic signals (vascular endothelial growth factor, basic
fibroblast growth factor, and matrix metalloproteinase 9)
and result in growth arrest. Long-term effects of propran-
olol are characterized by induction of apoptosis in prolif-
erating endothelial cells and result in tumor regression
(Storch and Hoeger 2010; Le´aute´-Labre`ze et al. 2008;
Sarialioglu et al. 2010; Sans et al. 2009; Buckmiller et al.
2010).
Table 1 Changes in expression levels of the genes in NF-KB
pathway
Genes Control 20 50 100
NFKB2 100 200 227 613
RELB 100 1,108 1,411 11,164
NFKBIA 100 72 69 47
NFKBIB 100 503 241 524
NFKBIE 100 171 297 789
NKIRAS1 100 31 517 486
NKIRAS2 100 0 164 453
IKBKB 100 131 50 256
IKBKG 100 0 245 919
BTRC 100 101 243 466
CHUK 100 119 236 204
RIPK1 100 62 450 628
TBK1 100 24 106 426
IL10 100 366 1,611 0
IL6 0 100 234 0
IL8 100 104 882 1,204
IRAK1BP1 100 255 71 0
IRAK2 100 0 49,456 39,618
TNF 100 408 361 938
TNFAIP3 100 121 93 68
TNFRSF10B 100 429 13,814 63,915
TNFRSF1A 100 293 62 153
TNFSF15 100 3,406 246 42
LTA 100 378 711 1,851
TLR1 100 517 10,990 0
TLR2 0 100 0 4,784
TLR3 100 2,476 0 2,710
TLR6 100 11,536 2,581 0
TLR9 100 238 0 45
TRAF1 100 7 0 945
TRAF2 100 281 201 406
TRAF3 100 279 47 140
TRAF4 100 489 373 1,336
TRAF5 100 57 66 129
ZNF675 100 0 203 57
MAP3K1 100 138 486 664
MAP3K14 100 72 235 524
BCL10 100 0 682 318
BCL2 100 46 22 56
CD40 100 2,054 0 0
CD83 100 34 57 48
AKT1 100 30 103 0
CREB1 100 126 168 193
CREBBP 100 0 453 150
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Our data in agreement with each other revealed that
propranolol inhibited proliferation of U266 human multiple
myeloma cells in a time- and dose-dependent manner.
Propranolol increased caspase-3 enzyme activity, as an
important sign of apoptosis, and it also induced the loss of
mitochondrial membrane potential in a time- and dose-
dependent manner. FITC AnnexinV/PI double staining by
flow cytometry also confirmed time- and dose-dependent
apoptotic effects of propranolol on multiple myeloma cells.
When all the findings obtained are evaluated totally, it has
been displayed that the propranolol has antiproliferative
and apoptotic effects on U266 human multiple myeloma
cells.
MM is a malignant plasma cell disorder and it was first
described in 1873 by J. Von Rustizky (Buckmiller et al.
2010). Typical clinical and laboratory features in patients
with MM include bone pain, lytic lesions, osteoporosis,
anemia, renal failure, hypercalcaemia, and increased sus-
ceptibility of infections (Mahindra et al. 2010; Minnema
et al. 2010). In conclusion, multiple myeloma is a complex
disease having a number of complications and therapeutic
challenges. Unfortunately, complete cure is not succeeded
yet for multiple myeloma. Much progress has been made in
the treatment of patients with MM. Therefore, MM is rel-
atively resistant to conventional chemotherapeutic agents.
The introduction of new drugs such as thalidomide, bort-
ezomib, and lenalidomide has created more possibilities for
patients than many years before (Minnema et al. 2010).
Therefore, both multiple myeloma and these new therapies
often affect the renal, immune, skeletal, hematologic, and
nervous systems. We need new but less toxic drugs for
patients with multiple myeloma. With 40 years of exten-
sive clinical experience, there is no documented case of
death or serious cardiovascular morbidity resulting directly
from b-adrenergic receptor blocker exposure. However,
several well-known side effects, such as bradycardia and
hypotension, justify close monitoring at the onset of
treatment (Emilien and Maloteaux 1998; Frohlich 1977;
Featherstone 1983; Lee et al. 1982).
The results of this study showed that treatment of U266
human multiple myeloma cells with increasing concentra-
tions of propranolol affected the expression levels of some
important genes involved in upstream and downstream
targets of NF-jB signaling pathway which is the main
targets of multiple myeloma treatment. BCL10 gene
encoding B-cell lymphoma/leukemia 10 protein was
upregulated in response to propranolol. BCL10 gene con-
tributes to the proliferation of lymphocytes through acti-
vating NF-jB signaling and induces apoptosis through the
recruitment of caspases (Du and Isaccson 2002; Willis
et al. 1999). B-cell lymphoma 2 (Bcl-2) gene encodes an
anti-apoptotic protein, which is overexpressed in several
types of cancer such as leukemia, breast cancer, melanoma,
and prostate cancer and its overexpression often results in
drug resistance (Karnak and Xu 2010; Levine et al. 2008).
In addition to the regulation of apoptosis, Bcl-2 also
inhibits autophagy via forming a complex with Beclin-1
(Marquez and Xu 2012). In our study, decrements in
expression levels of Bcl-2 in response propranolol treat-
ment were observed. TRAFs communicate with signaling
molecules such as NF-jB and also with cell surface pro-
teins. This protein family has six members, and all of them
are known to regulate apoptotic events and stress-mediated
cellular responses. Some of these proteins (TRAF-2,
TRAF-5, and TRAF-6) are known to trigger NF-jB sig-
naling pathway (Bradley and Pober 2001). It is also known
that TRAF-1/TRAF-2 complex formation causes the
recruitment of anti-apoptotic signals via interacting with
the proteins that are members of IAP family (Yoneda et al.
2000; Wajant et al. 2001). Our results demonstrated that
propranolol treatment causes increments in expression
levels of TRAF family members. Toll-like receptor family
(TLRs) members, important regulators of innate immune
system, recognize foreign substances and pathogenic par-
ticles, and then trigger the synthesis of appropriate cyto-
kines, and also activate NF-jB (Do et al. 2012). Davoodi
et al. reported that TLR expression increases the activity of
NF-jB in colorectal cancer cells (Davoodi et al. 2012). In a
recent study, it has been reported that TLRs can be
potential targets for cancer therapy (Connolly and O’Neill
2012). Our results showed that there were significant
increases in expression levels of TLR1-4. Tumor necrosis
factor receptor superfamily member 10b (TNFRSF10B)
gene includes a death domain inducing apoptotic events. It
was previously reported that TNFRSF10B could be a tumor
suppressor gene since it triggered p53-mediated apoptosis
in cancer cells (Takimoto and El-Deiry 2000). In addition,
another study also reported that treatment of K562 human
chronic myeloid cells with an inhibitor of histone deace-
tylase, KBH-A42, caused TNFRSF10B overexpression and
resulted in apoptosis (Kang et al. 2012). Our results are in
consistent with the literature and revealed that propranolol
treatment resulted in considerable increment in the
expression levels of TNFRSF10B gene in a dose-dependent
manner. Interleukins are the genes encoding different types
of cytokines. IL-10 was reported to suppress the activity of
NF-jB and also to increase the survival and proliferation of
B cells (Eskdale et al. 1997). Our results showed that
propranolol treatment increased interleukin expression. In
addition, while the expression levels of NF-jB have
increased in response to propranolol treatment, the inhibi-
tors of NF-jB genes were also highly overexpressed in
response to propranolol in U266 cells.
In conclusion, taking together, all these data showed
antiproliferative and apoptotic effects of propranolol on
multiple myeloma cells. When we look at the final outcome
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from the responses of the cells to propranolol, we can argue
that both apoptotic and antiapoptotic, tumor suppressor,
prosurvival, and also inflammatory genes are activated via
propranolol treatment, but the expression of antiapoptotic
and tumor suppressor genes may eliminate the effects of
the other genes. On the other hand, propranolol has been
well studied in adults and infants (Metry et al. 2012). The
most common serious adverse effects of propranolol are
bradycardia and hypotension (Metry et al. 2012; Zusman
et al. 1987). Propranolol can be used in high doses but even
these concentrations do not have serious adverse effects
(Zusman et al. 1987). On the other hand, it is very well
known that 320 mg/day propranolol was used in hyper-
tension (Zusman et al. 1987). Therefore, the effective
concentrations of propranolol as determined in this study
can be accepted. But still effective dose of propranolol
should be optimized for in vivo applications.
These results may open the way of the treatment for
multiple myeloma for the treatment procedure of MM
patients. Therefore, further research to evaluate proprano-
lol application to multiple myeloma is needed.
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